{
    "nct_id": "NCT06142396",
    "official_title": "Pilot Study of Daratumumab in Combination With Bortezomib, Cyclophosphamide, and Dexamethasone (Dara-CyBorD) in Newly Diagnosed Multiple Myeloma Patients With Renal Failure",
    "inclusion_criteria": "1. Patients must have had a confirmed new diagnosis of MM following revised IMWG criteria.\n2. Patients must have Zubrod/ECOG Performance Status ≤ 2.\n3. Patients must have renal insufficiency. Renal insufficiency is defined as eCrCl < 60 mL/min (using Cockcroft-Gault Equation for Cr Cl) and/or necessitating dialysis\n4. must not have known allergies to any of the study drugs. Must have adequate organ function.\n5. International normalized ratio (INR) and prothrombin time (PT) ≤1.5 × ULN. Activated partial thromboplastin time (aPTT) ≤1.5 × ULN.\nHealthy volunteers allowed\nMust have minimum age of 18 Years\nMust have maximum age of 80 Years",
    "exclusion_criteria": "* 1. Known seropositive for: human immunodeficiency virus (HIV), Hepatitis B, or Hepatitis C.\n\n  2. Known Chronic obstructive pulmonary disease (COPD). 3. Known Moderate or severe persistent asthma within the past 2 years, or uncontrolled asthma of any classification.\n\n  4. Known Clinically significant heart disease is defined as: myocardial infarction within 6 months before enrollment, or unstable or uncontrolled disease/condition related to or affection cardiac function.\n\n  5. Women who are pregnant, breastfeeding, or planning to become pregnant while enrolled in this study.\n\n  6. Patients with grade 3 or 4 peripheral neuropathy 7. Patients with other active malignancies that require concurrent treatment 8. Known CNS involvement or plasma cell leukemia, or AL amyloidosis 9. Participants with active infection requiring systemic therapy 10. Has known substance abuse disorders that would interfere with cooperation with the requirements of the study.",
    "miscellaneous_criteria": ""
}